M&A news: Luye Pharma of China will pay $599 million to acquire a 58% stake in Beijing Jialin Pharmaceutical Co., a company that makes drug products for cardiovascular diseases and cancer.
In 2013, Jialin produced $185 million of revenue.
According to Luye, the m&a deal will add to its portfolio of cardiovascular drugs and broaden its sales network.
For further deal information visit Current Agreements (subscription required)
Read: more on M&A deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Pharma and Biotech M&A Trends 2009-2014
View: Current Partnering’s M&A Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Partnering activity – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Parnering activity – latest trends in big biotech deal making activity